A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of AC-201 Tablets in Subjects With Moderate-to-severe Plaque Psoriasis
Latest Information Update: 24 May 2025
At a glance
- Drugs AC-201-Accropeutics (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Most Recent Events
- 20 May 2025 Primary endpoint (Percentage of subjects achieved Psoriasis Area Severity Index (PASI) 75 at Week 12) has been met, according to an Accropeutics Media Release
- 20 May 2025 Results presented in an Accropeutics Media Release.
- 05 Mar 2025 New trial record